{'fraction_non_alphanumeric': 0.05032021957913998, 'fraction_numerical': 0.0384263494967978, 'mean_word_length': 4.47, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Liver transection using the LigaSure sealing system.

BACKGROUND
The aim of the present study was to evaluate the feasibility and efficacy of the LigaSure vessel sealing system on a large scale when used for liver resection.


METHODS
We retrospectively analyzed the short-term outcomes of 277 patients undergoing hepatectomies with the use of the LigaSure system.


RESULTS
There were two hospital deaths (0.7%), and the morbidity rate was 25.3%. Mean blood loss during liver transection was 352+/-422 ml, and the liver transection speed was 1.9+/-0.86 cm(2)/min. The number of ties required during liver transection was 13.2+/-13. The morbidity and mortality rate was similar when comparing patients with injured livers (chronic hepatitis or cirrhosis) and those with normal livers, but liver transection speed was faster in those with normal livers when compared with those with injured livers (2.00+/-0.88 vs. 1.57+/-0.63 cm(2)/min, p=0.001).


CONCLUSIONS
The LigaSure system can be applied safely in patients undergoing liver resection, regardless of whether cirrhosis is present or not.